Bayer seeks Japanese marketing approval for finerenone to treat adult patients with chronic heart failure: Berlin Saturday, February 15, 2025, 14:00 Hrs [IST] Bayer announced the ...

A recent study from the FINEARTS-HF trial revealed that finerenone, which is an oral mineralocorticoid receptor antagonist, ...

Finerenone treatment vs placebo was associated with a reduced risk for new-onset diabetes by 24% among patients with HFmrEF or HFpEF.

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

Berlin: Bayer has announced the submission of a marketing authorization application to the European Medicines Agency (EMA), ...

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients ...

Finerenone – billed as a first-in-class non-steroidal, selective mineralocorticoid receptor (MR) antagonist – reduced the risk of kidney disease progression or renal death by 18% when added to ...

Over a median of 32 months, finerenone significantly reduced the primary endpoint, with 1,083 events in the finerenone group and 1,283 events in the placebo group (rate ratio 0.84; 95% confidence ...